Clinical Trials Directory

Trials / Completed

CompletedNCT01533519

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

A Dose Escalation Study of Intranasal Neuropeptide Y in PTSD

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
26 (actual)
Sponsor
James Murrough · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This study is designed to investigate the safety of intranasal administration of NPY using a dose escalation, randomized, double-blinded, placebo-controlled crossover design in a medication-free, symptomatic PTSD group.

Conditions

Interventions

TypeNameDescription
DRUGNeuropeptide YIntranasal administration will be administered with a nasal drug delivery device.

Timeline

Start date
2012-12-01
Primary completion
2016-01-01
Completion
2016-01-01
First posted
2012-02-15
Last updated
2016-04-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01533519. Inclusion in this directory is not an endorsement.